Sana Alajmovic, founder and CEO of Sigrid Therapeutics, was voted the winner of the Female Founders competition 2021 as voted for by readers of the publication Dagens Industri.
“It’s a great honor, not least because many of the others nominated are my role models. It has been my goal to get more people outside the life science industry to pay attention to Sigrid and our work to prevent lifestyle diseases and contribute to a healthier world,” says Sana Alajmovic.
Sigrid Therapeutics, which Sana Alajmovic founded together with Tore Bengtsson, professor of physiology at Stockholm University, aims to prevent two of the world’s fastest growing lifestyle diseases – type 2 diabetes and obesity. Their lead product SiPore15 is a silica powder which can be easily taken mixed with water or food. SiPore15 does not enter the bloodstream, but instead acts locally in the gut by trapping the enzymes responsible for breaking down carbohydrates and fats. This enables blood sugar and other key levels to be managed, the company states.
Plans to launch a new product
The new share issue that recently raised SEK 72 million will be used to carry out one of the world’s largest clinical studies on prediabetics and newly diagnosed type 2 diabetics in Europe in order to form the basis for the application for approval for SiPore15 as a medical device when completed.
Sigrid also has plans to launch a new product, based on the company’s platform technology SiPore, in the nutritional supplement market in 2022.
Photo of Sana Alajmovic: Pax Engstrom